Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2020-02-05 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
关于控股股东部分股份质押的公告
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding the pledge of shares by the controlling shareholder and its related parties. It includes detailed information about the number of shares pledged, the proportion of shares pledged relative to total holdings and company shares, financial data of the controlling shareholder and related entities, and assurances about the impact of the pledge on the company. The document does not contain a full financial report or earnings data but is a regulatory disclosure about share pledging activities. This fits the category of a Capital/Financing Update (CAP), as it relates to financing activities involving share pledges by major shareholders. The document length and content confirm it is not a brief announcement or a report publication notice but a substantive update on capital structure related to share pledges.
2020-02-05 Chinese
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is titled as a "股票交易异常波动公告" which translates to "Announcement of Abnormal Stock Trading Fluctuations." It discusses the unusual price movements of the company's stock over specific dates and provides explanations and clarifications regarding the situation. It includes statements from the board, information about the company's recent activities, and risk warnings to investors. The document is an announcement related to stock trading behavior and does not contain financial statements, audit information, or detailed financial results. It is not a report like an Annual Report or Interim Report, nor is it a certification or voting result. Given the nature of the content and the length (1959 characters), it fits best into the category of Regulatory Filings (RNS), which is a fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-02-03 Chinese
关于全资子公司取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding its wholly-owned subsidiary obtaining medical device registration certificates for COVID-19 nucleic acid testing products. It includes details about the certificates, product descriptions, regulatory approval by the National Medical Products Administration, and the impact on the company. The document is an official announcement of a regulatory approval event and does not contain financial statements, management discussion, or detailed financial data. It is not a report like an Annual Report, Interim Report, or Earnings Release. It is also not a voting result, board change, or legal proceeding. The document is a regulatory announcement about product registration and approval, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories. The document length is short (2113 characters), and it is not announcing the publication of a report but rather a regulatory approval event. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2020-02-02 Chinese
2019年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2019 annual performance forecast (业绩预告) for Shenzhen BGI Genomics Co., Ltd. It covers the expected financial results for the full fiscal year 2019 (January 1 to December 31, 2019). The text explicitly states that the forecast is unaudited and that detailed financial data will be disclosed in the 2019 annual report. The document is relatively short (2306 characters) and serves as a preliminary earnings outlook rather than a full financial report. This matches the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. It is not a full Annual Report (10-K) or Interim Report (IR) because it lacks comprehensive financial statements and detailed analysis. Therefore, the correct classification is Earnings Release (ER). FY 2019
2020-01-23 Chinese
关于转让控股子公司深圳华大因源医药科技有限公司部分股权及放弃增资的优先认购权暨关联交易进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the transfer of partial equity in a controlling subsidiary and the waiver of preemptive rights for capital increase, including details of the transaction, investment agreements, and registration changes. It is a corporate disclosure about a capital transaction involving a subsidiary, with no financial statements or earnings data presented. The document length is 3127 characters, relatively short and focused on transaction progress and regulatory compliance disclosures. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2020-01-20 Chinese
2020年第一次临时股东大会之法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, attendance, and voting procedures of Shenzhen BGI Genomics Co., Ltd.'s 2020 First Extraordinary General Meeting of Shareholders. It details the legality and compliance of the meeting's procedures with relevant laws and company rules. It does not contain financial statements, earnings data, or management discussion of financial results. It is not a report of voting results per se but a legal opinion on the meeting's conduct. The document is not a report publication announcement or a certification letter but a legal opinion related to a shareholders meeting. Given the content, the best fitting category is "Declaration of Voting Results & Voting Rights Announcements (DVA)" because it includes detailed voting results and legal validation of those results from the meeting. Confidence is high due to the detailed voting data and legal opinion on the meeting's validity.
2020-01-14 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.